Wealth Enhancement Advisory Services LLC Has $765,000 Stake in Prestige Consumer Healthcare Inc. $PBH

Wealth Enhancement Advisory Services LLC increased its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 13.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,571 shares of the company’s stock after buying an additional 1,134 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Prestige Consumer Healthcare were worth $765,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Cerity Partners LLC raised its position in shares of Prestige Consumer Healthcare by 3.7% in the first quarter. Cerity Partners LLC now owns 3,666 shares of the company’s stock valued at $315,000 after buying an additional 132 shares in the last quarter. KBC Group NV raised its position in shares of Prestige Consumer Healthcare by 7.4% in the first quarter. KBC Group NV now owns 2,199 shares of the company’s stock valued at $189,000 after buying an additional 151 shares in the last quarter. Xponance Inc. raised its position in shares of Prestige Consumer Healthcare by 5.5% in the first quarter. Xponance Inc. now owns 3,766 shares of the company’s stock valued at $324,000 after buying an additional 196 shares in the last quarter. Resona Asset Management Co. Ltd. raised its position in shares of Prestige Consumer Healthcare by 2.3% in the first quarter. Resona Asset Management Co. Ltd. now owns 9,105 shares of the company’s stock valued at $783,000 after buying an additional 203 shares in the last quarter. Finally, Alliance Wealth Advisors LLC UT raised its position in shares of Prestige Consumer Healthcare by 2.2% in the first quarter. Alliance Wealth Advisors LLC UT now owns 11,783 shares of the company’s stock valued at $1,013,000 after buying an additional 254 shares in the last quarter. 99.95% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on PBH. Wall Street Zen downgraded shares of Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th. Zacks Research downgraded shares of Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research report on Thursday, September 4th. Canaccord Genuity Group decreased their price objective on shares of Prestige Consumer Healthcare from $105.00 to $100.00 and set a “buy” rating on the stock in a research note on Friday, August 8th. Finally, Sidoti raised shares of Prestige Consumer Healthcare from a “neutral” rating to a “buy” rating and set a $80.00 price objective on the stock in a research note on Wednesday, September 24th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Prestige Consumer Healthcare has an average rating of “Moderate Buy” and a consensus price target of $94.80.

Prestige Consumer Healthcare Stock Performance

NYSE PBH opened at $62.78 on Friday. The firm’s fifty day moving average price is $66.74 and its two-hundred day moving average price is $77.10. The stock has a market cap of $3.09 billion, a PE ratio of 14.74, a PEG ratio of 2.00 and a beta of 0.44. Prestige Consumer Healthcare Inc. has a fifty-two week low of $61.28 and a fifty-two week high of $90.04. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.99 and a current ratio of 4.38.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Thursday, August 7th. The company reported $0.95 earnings per share for the quarter, missing analysts’ consensus estimates of $1.01 by ($0.06). The company had revenue of $249.53 million for the quarter, compared to the consensus estimate of $260.71 million. Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%.The business’s quarterly revenue was down 6.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.90 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. On average, equities analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.